A More Rational Approach for Sterile Product Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A More Rational Approach for Sterile Product Manufacturing
The authors assert that the current gulf between aseptic processing and terminal sterilization can be bridged by re-examining fundamental regulatory philosophies for sterile-product manufacturing.

Pharmaceutical Technology
Volume 36, Issue 5, pp. s48-s50

Parametric release

Dr. Tsuguo Sasaki, GMP Expert, Office of Compliance and Standards of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) advocates that F ≥ 2 min would be a reasonable expectation for parametric release. The authors strongly agree and would favor a harmonized regulatory approach in which any firm with acceptable GMP compliance that submitted an application for a product sterilized at a process lethality of F ≥ 2 min would be granted parametric release for its product without any added expectations. This proposal is radical only because existing regulatory policy fails to properly consider true medical risk.

Parametric release simply means releasing product without having subjected it to a compendial sterility test. The real question is what value the performance of a sterility test on a process offers. Given the low sensitivity and statistical sampling limitations of the sterility test, it has limited value and really should be called a test for gross product contamination. It is rarely failed when applied to aseptically produced products and simply has no value when used to test products sterilized in their containers.

Postfill treatments

Lower temperature heat treatments would provide significant safety benefit to products that are filled in human-scale cleanrooms. The benefit of these treatments would diminish in instances where advanced aseptic processing technologies, such as isolators, closed restricted access barrier systems, or some blow, fill, and seal processes are used. The authors postulate that comparable approaches could be used with radiation sterilization where low-dose exposures would provide similar advantages to patient safety. ISO 11137-2 provides for developing relatively low does processes based upon bioburden number and resistance (1).

Recommendations and experience from Japan

PMDA's Dr. Sasaki shared with the authors some basic concepts from Japan's Guideline on the Manufacture of Sterile Drugs by Terminal Sterilization, which is expected to be issued in 2012. This document will consist of a narrative section and annexes. The following information reflects general recommendations for low F terminal sterilization and will be presented in one of the guideline's annexes:

  • Minimum F is 2.0.
  • Cleanliness of filling area is Grade A, and surrounding areas are Grade B. (Grade C may also be used but personnel microbial monitoring would be expected to meet Grade B levels.)
  • Average presterilization bioburden should be less than 1 colony-forming unit (cfu)/product unit.
  • Bioburden should be evaluated for heat resistance.
  • Grade A is used for filling, but media fill testing is not required.

Table I: Application of low-dose sterilization from 13 manufacturers in Japan from 2005–2010.
Low-dose terminal sterilizational is in widespread use in Japan. Dr. Sasaki provided some data regarding its application in Japan during 2005–2010 from 13 different manufacturers (see Table 1). Nearly 80% of the roughly 2.8 trillion units manufactured by terminal sterilization were subjected to F of two minutes or less. Quite clearly, these low lethality sterilization processes would not be allowed were they not safe and efficacious.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here